Benefits of renin-angiotensin blockade on retinopathy in type 1 diabetes vary with glycemic control

Diabetes Care

Volumn 34, Issue 8, 2011, Pages 1838-1842

  Harindhanavudhi, Tasma ^a   Mauer, Michael ^a   Klein, Ronald ^b   Zinman, Bernard ^c   Sinaiko, Alan ^a   Caramori, M Luiza ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ENALAPRIL; HEMOGLOBIN A1C; LOSARTAN; PLACEBO; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLYCOSYLATED HEMOGLOBIN;

ADULT; ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; DIABETIC RETINOPATHY; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG EFFICACY; FEMALE; GLYCEMIC CONTROL; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; PATIENT ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; RENAL PROTECTION; RISK BENEFIT ANALYSIS; TREATMENT DURATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG EFFECT; GLUCOSE BLOOD LEVEL; METABOLISM; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

ADULT; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 1; DIABETIC RETINOPATHY; ENALAPRIL; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; LOSARTAN; MALE; RENIN-ANGIOTENSIN SYSTEM; YOUNG ADULT;

EID: 84856007395     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc11-0476     Document Type: Article

References (25)

1. Fong DS, Aiello L, Gardner TW, et al.; American Diabetes Association. Retinopathy in diabetes. Diabetes Care 2004;27(Suppl. 1):S84-S87 (Pubitemid 38197476)
2. Zhang X, Saaddine JB, Chou CF, et al. Prevalence of diabetic retinopathy in the United States, 2005-2008. JAMA 2010;304:649-656
3. Saaddine JB, Honeycutt AA, Narayan KM, Zhang X, Klein R, Boyle JP. Projection of diabetic retinopathy and other major eye diseases among people with diabetes mellitus: United States, 2005-2050. Arch Ophthalmol 2008;126:1740-1747
4. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-853
5. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-986
6. American Diabetes Association. Standards of medical care in diabetes-2011. Diabetes Care 2011;34(Suppl. 1):S11-S61
7. Nathan DM, Zinman B, Cleary PA, et al.; Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Research Group. Modern-day clinical course of type 1 diabetes mellitus after 30 years' duration: the diabetes control and complications trial/epidemiology of diabetes interventions and complications and Pittsburgh epidemiology of diabetes complications experience (1983-2005). Arch Intern Med 2009;169:1307-1316
8. Matthews DR, Stratton IM, Aldington SJ, Holman RR, Kohner EM; UK Prospective Diabetes Study Group. Risks of progression of retinopathy and vision loss related to tight blood pressure control in type 2 diabetes mellitus: UKPDS 69. Arch Ophthalmol 2004;122:1631-1640 (Pubitemid 39473407)
9. Schrier RW, Estacio RO, Esler A, Mehler P. Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. Kidney Int 2002;61:1086-1097 (Pubitemid 34175478)
10. Jackson WE, Holmes DL, Garg SK, Harris S, Chase HP. Angiotensin- converting enzyme inhibitor therapy and diabetic retinopathy. Ann Ophthalmol 1992;24:99-103
11. Chase HP, Garg SK, Harris S, Hoops S, Jackson WE, Holmes DL. Angiotensin-converting enzyme inhibitor treatment for young normotensive diabetic subjects: a two-year trial. Ann Ophthalmol 1993;25:284-289
12. Chaturvedi N, Sjolie AK, Stephenson JM, et al. Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. The EUCLID Study Group. EURODIAB Controlled Trial of Lisinopril in Insulin-Dependent Diabetes Mellitus. Lancet 1998;351:28-31
13. Mauer M, Zinman B, Gardiner R, et al. Renal and retinal effects of enalapril and losartan in type 1 diabetes. N Engl J Med 2009;361:40-51
14. Chaturvedi N, Porta M, Klein R, et al.; DIRECT Programme Study Group. Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trials. Lancet 2008;372:1394-1402
15. Mauer M, Zinman B, Gardiner R, et al. ACE-I and ARBs in early diabetic nephropathy. J Renin Angiotensin Aldosterone Syst 2002;3:262-269 (Pubitemid 36181996)
16. Andersen S, Tarnow L, Rossing P, Hansen BV, Parving HH. Renoprotective effects of angiotensin II receptor blockade in type 1 diabetic patients with diabetic nephropathy. Kidney Int 2000;57:601-606 (Pubitemid 30430652)
17. Early Treatment Diabetic Retinopathy Study Research Group. Grading diabetic retinopathy from stereoscopic color fundus photographs - an extension of the modified Airlie House classification. ETDRS report number 10. Ophthalmology 1991;98(Suppl.):786-806
18. Klein R, Zinman B, Gardiner R, et al.; Renin-Angiotensin System Study. The relationship of diabetic retinopathy to preclinical diabetic glomerulopathy lesions in type 1 diabetic patients: the Renin-Angiotensin System Study. Diabetes 2005;54:527-533
19. Klein BE, Davis MD, Segal P, et al. Diabetic retinopathy. Assessment of severity and progression. Ophthalmology 1984;91:10-17 (Pubitemid 14184711)
20. Early Treatment Diabetic Retinopathy Study Research Group. Fundus photographic risk factors for progression of diabetic retinopathy. ETDRS report number 12. Ophthalmology 1991;98(Suppl.):823-833
21. Klein R, Klein BE, Moss SE. How many steps of progression of diabetic retinopathy are meaningful? The Wisconsin epidemiologic study of diabetic retinopathy. Arch Ophthalmol 2001;119:547-553 (Pubitemid 32290063)
22. Bröchner-Mortensen J, Giese J, Rossing N. Renal inulin clearance versus total plasma clearance of 51Cr-EDTA. Scand J Clin Lab Invest 1969;23:301-305
23. Gaspari F, Perico N, Remuzzi G. Application of newer clearance techniques for the determination of glomerular filtration rate. Curr Opin Nephrol Hypertens 1998;7:675-680 (Pubitemid 28551671)
24. Gaspari F, Perico N, Matalone M, et al. Precision of plasma clearance of iohexol for estimation of GFR in patients with renal disease. J Am Soc Nephrol 1998;9:310-313 (Pubitemid 28092081)
25. Bilous R, Chaturvedi N, Sjølie AK, et al. Effect of candesartan on microalbumiuria and albumin excretion rate in diabetes: three randomized trials. Ann Intern Med 2009;151:11-20